CLINUVEL PHARMACEUTICALS

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

CLINUVEL’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

12 April 2017

Lapse and Forfeit of Unlisted Conditional Performance Rights

Lapse and Forfeit of Unlisted Conditional Performance Rights

Read More
12 April 2017

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

Read More
31 January 2017

Appendix 4C - Quarterly report

Quarterly report

Read More
23 December 2016

Appendix 3Y

Change of Director’s Interest Notice

Read More

Quick Links